Skip to Content

Rituxan Hycela Approval History

FDA Approved: Yes (First approved June 22, 2017)
Brand name: Rituxan Hycela
Generic name: rituximab and hyaluronidase human
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Follicular Lymphoma; Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia

Rituxan Hycela (rituximab and hyaluronidase human) is a subcutaneous monoclonal antibody and hyaluronidase human formulation for the treatment of adult patients with follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

Development History and FDA Approval Process for Rituxan Hycela

DateArticle
Jun 22, 2017Approval FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide